Brief: Aurinia Pharmaceuticals Q2 Product Revenue USD 55.028 Million
01/08/2024 11:00
Aug 01 (Reuters) - Aurinia Pharmaceuticals Q2 operating income USD -1.513 million. * Q2 net income USD 722 thousand * Q2 pretax profit USD 1.478 million
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death